\n<\/p>\n
BEIJING, CHINA – Central to the collaboration, which jointly aims to assess and conduct direct investments in the life sciences industry, is the eagerness to invest in the world’s leading innovators in the sector and become their trusted partner in their expansion into the Greater China Region<\/b>. Bringing these innovative companies to the region will yield a plethora of benefits for the already highly sophisticated Chinese life sciences sector. Cedrus will leverage its connectivity across the life sciences industry globally, along with its For over a decade, Cedrus has been actively engaged in bringing foreign
\nMedia OutReach<\/a> – 16 May 2023 –
\nCedrus Group<\/b> (“Cedrus”)<\/a>, a global Swiss financial group, is pleased to announce that it has signed a
\ncollaboration agreement with Xiuzheng Pharmaceutical Group (“Xiuzheng”)<\/b> in March 2023. Xiuzheng is a renowned Chinese pharmaceutical major; namely, it engages in R&D, production and marketing of patent medicine, chemical and biological medicine, franchise operation of pharmacies, and standardized cultivation of Traditional Chinese Medicine (TCM).
\nXiuzheng owns 130 subsidiaries, employs a workforce of over 100,000 and has more than 2,000 references of medicines and health foods.<\/b><\/p>\n
\ndeploying its distinguished investment banking services and capitalizing on its European headquarters in Zurich,<\/b> to act as a holistic enabler and connector between Xiuzheng and overseas technologies and products in the course successfully executing cross-border transactions. Additionally, Cedrus will advise Xiuzheng in order to
\nestablish itself on a global-scale<\/b> and
\nwrite further chapters in its success story<\/b>. In addition to investment, Xiuzheng will provide valuable support to the opportunities brought to China, namely in the form of clinical trials advisory, access to manufacturing partners and utilizing its experienced work force to market and distribute products. <\/b>\n<\/p>\n
\ninnovative technologies, products and treatments from across the life sciences space,<\/b> in particular from Switzerland and other European countries to the Greater China region. Cedrus, in its capacity as an investor and advisor, identifies visionary companies looking to gain
\nearly access to one of the largest pharmaceutical markets in the world<\/b> and partners with them, offering investment and ongoing advisory in their market entry and growth in China.\n<\/p>\n